Wall Street analysts forecast that Becton Dickinson (BDX) will report quarterly earnings of $3.14 per share in its upcoming release, pointing to a year-over-year decline of 14.7%. It is anticipated that revenues will amount to $4.89 billion, exhibiting a decrease of 11.2% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Given this perspective, it's time to examine the average forecasts of specific Becton Dickinson metrics that are routinely monitored and predicted by Wall Street analysts.
Analysts expect 'Revenues- Interventional' to come in at $1.39 billion. The estimate indicates a year-over-year change of +4.9%.
The consensus estimate for 'Revenues- Interventional- Surgery' stands at $417.50 million. The estimate indicates a change of +5.7% from the prior-year quarter.
It is projected by analysts that the 'Revenues- Interventional- Peripheral Intervention' will reach $528.50 million. The estimate indicates a year-over-year change of +3.2%.
Analysts predict that the 'Revenues- Interventional- Urology and Critical Care' will reach $447.64 million. The estimate indicates a change of +6.1% from the prior-year quarter.
Analysts' assessment points toward 'Revenues- Connected Care- Medication Management Solutions- International' reaching $178.72 million. The estimate points to a change of -0.2% from the year-ago quarter.
The combined assessment of analysts suggests that 'Revenues- Connected Care- Medication Management Solutions- United States' will likely reach $711.11 million. The estimate points to a change of +0.3% from the year-ago quarter.
The consensus among analysts is that 'Revenues- Interventional- Peripheral Intervention- United States' will reach $282.52 million. The estimate points to a change of +4.3% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Revenues- Interventional- Urology and Critical Care- United States' of $358.22 million. The estimate points to a change of +7.3% from the year-ago quarter.
The average prediction of analysts places 'Revenues- Interventional- United States' at $947.23 million. The estimate indicates a change of +5.5% from the prior-year quarter.
According to the collective judgment of analysts, 'Revenues- Interventional- Surgery- International' should come in at $111.26 million. The estimate points to a change of +10.2% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenues- Interventional- Peripheral Intervention- International' should arrive at $249.73 million. The estimate indicates a year-over-year change of +3.6%.
Analysts forecast 'Revenues- Interventional- Urology and Critical Care- International' to reach $90.75 million. The estimate points to a change of +3.1% from the year-ago quarter.
View all Key Company Metrics for Becton Dickinson here>>>Shares of Becton Dickinson have demonstrated returns of +9.4% over the past month compared to the Zacks S&P 500 composite's +1.7% change. With a Zacks Rank #4 (Sell), BDX is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Becton, Dickinson and Company (BDX): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).